Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 2, 2026Glycobiology

Protein O-Mannosyltransferases in Development and Disease: Evolutionary and Functional Insights from Model Organisms

View Full Paper
Ask AI
Bookmark
Share

Key result

POMT1/2 contribute to dystroglycanopathy phenotypes via dystroglycan-independent mechanisms in animal models.

Why the study?

Evidence indicates POMTs have functional substrates beyond dystroglycan that contribute to mutant phenotypes through dystroglycan-independent mechanisms in dystroglycanopathies.

Design

Review

Authors

CSCaden SummersTexas A&M University SystemSDSaniya DauletbayevaAl-Farabi Kazakh National UniversityBNBoris NovikovTexas A&M University System

Discussion

Loading...

Member takes

Implication

Broader POMT1/2 mechanisms should not yet alter clinical practice; leaves open dystroglycan-independent targets in human dystroglycanopathies.

Key Points

  • Synthesize evolutionary and functional insights regarding POMT1/2-mediated O-mannosylation and examine dystroglycan-independent disease mechanisms using model organisms.
  • Reviewed comparative developmental, genetic, and molecular studies across animal models, focusing on Drosophila melanogaster and zebrafish (Danio rerio).
  • Analyzed functional interactions and substrate profiles of the POMT1/2 enzyme complex in neuromuscular and neural development.
  • Drosophila models demonstrate that POMT1/2 regulates neural circuit formation and muscular integrity via receptor protein tyrosine phosphatases alongside dystroglycan.
  • Zebrafish POMT1/2 mutants recapitulate human multi-tissue dystroglycanopathy phenotypes, revealing endogenous compensatory mechanisms and dystroglycan-independent pathological features.
  • Cross-species functional analyses show that O-mannosylation of non-dystroglycan substrates contributes substantially to mutant phenotypes across evolutionarily divergent organisms.

Structured PICO

P
Population
Model organisms (Drosophila, zebrafish) and humans with dystroglycanopathies (POMT1/2 defects)

Animal models like Drosophila and zebrafish provide valuable insights into the dystroglycan-independent pathological mechanisms of POMT1/2 defects in congenital muscular dystrophies.

Cite This Study

Summers et al. (2026) conducted a review in Dystroglycanopathies. POMT1/2 was evaluated. Animal models reveal that POMT1/2 have functional substrates beyond dystroglycan, contributing to dystroglycanopathy phenotypes through dystroglycan-independent mechanisms.

synapsesocial.com/papers/6a97e318c562ede874ec7be8https://doi.org/10.1093/glycob/cwag071
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Protein O-mannosylation: one sugar, several pathways, many functions2023 · 15 citations
  2. 2The expanding phenotype ofPOMT1mutations: from Walker-Warburg syndrome to congenital muscular dystrophy, microcephaly, and mental retardation2006 · 113 citations
  3. 3Novel POMT2 variants associated with limb-girdle muscular dystrophy R14: genetic, histological and functional studies2025
  4. 4Global View of Domain-Specific O-Linked Mannose Glycosylation in Glycoengineered Cells2024 · 18 citations
  5. 5Global view of domain-specific O-linked mannose glycosylation in glycoengineered cells2024 · 1 citations